December 16, 2024
Beckley Psytech announces positive topline results from Phase IIa study of ELE-101 (IV psilocin benzoate) for Major Depressive Disorder
ELE-101 is Beckley Psytech's patent-protected synthetic intravenous (IV) formulation of psilocin benzoate designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours. In the small proof-of-concept study (n=6) in patients with Major Depressive Disorder (MDD), a single 10 minute infusion of ELE-101 was shown to induce rapid, robust and lasting antidepressant effects, with a mean >20 point reduction in MADRS scores observed at all time points through to 3 months after dosing. ELE-101 was also shown to be well-tolerated and patients were deemed ready to be discharged by Investigators within a mean time of approximately 2 hours. Study follow-up is complete and further data will be available in 2025 and will be used to inform the future clinical development of ELE-101.
… Read more